Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Without PBS subsidy for obesity indications, patients pay full price: Wegovy: approximately $320$450 per month Saxenda: approximately $390$440 per month Mounjaro (off-label for weight loss): approximately $280$750 per month depending on dose PBS listing for obesity indications is an ongoing discussion, with health economists and advocacy groups pushing for subsidised access given the long-term healthcare costs associated with untreated obesity
Ozempic operates by enhancing the bodys release of insulin when blood sugar levels are high, which is essential for lowering blood glucose levels
Provider Assessment and Shared Decision-Making for GLP-1 Treatment Safety Treatment initiation decisions should be collaborative and based on individual risk-benefit analysis
Higher concentrations may increase results but also increase irritation risk
Some of the newer drugs like semaglutide, which is known as Ozempic and Wegovy, and tirzepatide, which is known as Mounjaro and Zepbound these drugs have increased potency
